CTX

C-terminal telopeptide (CTX), also known as β-CTX or Beta-CrossLaps, is a biochemical marker of bone resorption. It measures the degradation products of type I collagen, which are released into the bloodstream during bone turnover. CTX is primarily used to assess the rate of bone resorption, providing insights into bone health and the dynamic process of bone remodeling. Clinically, CTX is significant in the diagnosis and management of osteoporosis, a condition characterized by increased bone fragility and fracture risk. Elevated CTX levels are associated with higher fracture risk, particularly in postmenopausal women, and can be used to monitor the effectiveness of osteoporosis treatments. For athletes and biohackers, CTX may offer insights into bone health and the effects of training or dietary interventions on bone turnover. However, the interpretation of CTX levels can be influenced by several factors, including time of day, fasting status, and renal function. Researchers have found that CTX levels exhibit diurnal variation, with higher values in the morning, and are affected by food intake, necessitating standardized testing conditions. Additionally, CTX levels may be elevated in individuals with chronic kidney disease due to impaired renal clearance, which can confound the assessment of bone resorption.